Global Information
회사소개 | 문의 | 비교리스트

헤파린 시장 : 규모, 점유율, 전망, 기회 분석(2018-2026년)

Heparin Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

리서치사 Coherent Market Insights
발행일 2019년 05월 상품 코드 865079
페이지 정보 영문
가격
US $ 4,500 ₩ 5,347,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,318,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 11,884,000 PPT Turned PDF (Enterprise User License)


헤파린 시장 : 규모, 점유율, 전망, 기회 분석(2018-2026년) Heparin Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
발행일 : 2019년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

헤파린은 항응고 저지 작용을 가지는 약품입니다. 관상동맥성 심장병, 폐색전증, 심부정맥혈전증 등의 유병수 증가에 의해 헤파린 수요가 증가하고 있습니다. 미국심장협회의 2018년 보고에 의하면 관상동맥성 심장병이 미국에서 심혈관질환에 의한 사망의 주요 원인(43.8%)이 되고 있습니다.

세계의 헤파린(Heparin) 시장을 조사했으며, 시장 개요, 제품 종류·제형·지역별 시장 규모 추정과 예측, 시장 성장 촉진요인 및 저해요인 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 연구 목적과 가정

  • 연구 목적
  • 가정
  • 약어

제2장 시장 개요

  • 보고서 설명
    • 시장 정의와 범위
  • 주요 요약
    • 시장 정보 : 제품 종류별
    • 시장 정보 : 제형별
    • 시장 정보 : 지역별
  • COM(Coherent Opportunity Map)

제3장 시장 역학, 규제, 시장 동향 분석

  • 개요
  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 영향 분석
  • 시장 동향
  • 주요 개발
  • 파이프라인 분석
  • 공급망 분석
  • 규제 개요
  • 역학 분석

제4장 세계의 헤파린 시장 : 제품 종류별

  • 서론
  • 미분획 헤파린(UH)
  • 저분자량 헤파린(LMWH)
  • 초저분자량 헤파린(ULMW)

제5장 세계의 헤파린 시장 : 제형별

  • 서론
  • 주사제
  • 용제

제6장 세계의 헤파린 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 중남미
  • 아프리카
  • 중동

제7장 경쟁 상황

  • 히트맵 분석
  • 기업 개요
    • Anselm Pharmaceuticals
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Bristol-Myers Squibb Co.
    • Dr. Reddy's Laboratories Ltd.
    • Fresenius SE & Co. KGaA
    • Leap Labchem Co.
    • LEO Pharma A/S
    • Pfizer, Inc.
    • Sanofi S.A.
    • Syntex S.A.
    • Teva Pharmaceutical Industries Ltd.
    • United Biotech(P) Ltd.
  • 애널리스트의 의견

제8장 섹션

  • 참고 문헌
  • 조사 방법
  • Coherent Market Insights 소개
KSM 19.06.21

Heparin is an anticoagulant used to decrease the clotting ability of blood and help to prevent harmful clots from forming in blood vessels. It is sometimes referred as a blood thinner, although it does not actually thin the blood. Heparin does not dissolve already formed blood clots, but it can prevent the clots from becoming larger and causing more serious problems. Pharmaceutical-grade heparin is derived from animal tissue. Heparin is commonly used in the treatment of coronary heart disease, pulmonary embolism, deep vein thrombosis, and atrial fibrillation, and in the prevention of thrombosis during extracorporeal membrane oxygenation and cardiopulmonary bypass.

Market Dynamics

Rising cases of conditions such as coronary heart disease, pulmonary embolism, and deep vein thrombosis is one of the major factors for increased demand of heparin drugs in the market. Myocardial infarction (MI) is one of the major complications of coronary heart disease. According to the American Heart Association 2018 report, coronary heart disease is the leading cause (43.8%) of deaths due to cardiovascular disease in the U.S., followed by stroke (16.8%). As per the Centres for Disease Control and Prevention (CDC) 2015 report, deep vein thrombosis affects nearly 900,000 individuals in the U.S. each year.

Despite major applications in chronic conditions, heparin is poorly absorbed by the intestine, therefore it must be given intravenously or subcutaneously. Moreover, the drug creates a significant risk of excessive bleeding due to anticlotting effect. Heparin also induce conditions such as thrombocytopenia (reduced number of circulating platelets) and hypersensitivity reactions. These factors can hamper the heparin market, during the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the heparin market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global heparin market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy's Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global heparin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for heparin market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Heparin Market, By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
  • Global Heparin Market, By Dosage Form:
    • Injection
    • Solutions
  • Global Heparin Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Product Type:
    • Unfractionated Heparin (UH)
    • Low Molecular Weight Heparin (LMWH)
    • Ultra-low Molecular Weight Heparin (ULMW)
      • By Dosage Form:
    • Injection
    • Solutions
  • Company Profiles
    • Anselm Pharmaceuticals*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Baxter International Inc.
    • B. Braun Melsungen AG
    • Bristol-Myers Squibb Co.
    • Dr. Reddy's Laboratories Ltd.
    • Fresenius SE & Co. KGaA
    • Leap Labchem Co.
    • LEO Pharma A/S
    • Pfizer, Inc.
    • Sanofi S.A.
    • Syntex S.A.
    • Teva Pharmaceutical Industries Ltd.
    • United Biotech (P) Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Dosage Form
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Overview
  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Pipeline Analysis
  • Supply Chain Analysis
  • Regulatory Landscape
  • Epidemiology Analysis

4. Global Heparin Market, By Product Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Unfractionated Heparin (UH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Low Molecular Weight Heparin (LMWH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Ultra-low Molecular Weight Heparin (ULMW)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Heparin Market, By Dosage Form, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Solution
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Heparin Market, By Region, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2016 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Northern Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage Form, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Anselm Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Baxter International Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • B. Braun Melsungen AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol-Myers Squibb Co.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Dr. Reddy's Laboratories Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Fresenius SE & Co. KGaA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Leap Labchem Co.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • LEO Pharma A/S
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Syntex S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • United Biotech (P) Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top
전화 문의
F A Q